Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Sofinnova Partners
Deal Size : $138.0 million
Deal Type : Series C Financing
Details : Amolyt plans to use the proceeds to advance its pipeline of therapeutics for rare endocrine and related disorders, including AZP-3601, now known as eneboparatide, for the treatment of hypoparathyroidism, and AZP-3813 for the treatment of acromegaly.
Product Name : AZP-3601
Product Type : Peptide
Upfront Cash : Undisclosed
June 01, 2023
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Sofinnova Partners
Deal Size : $138.0 million
Deal Type : Series C Financing
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AZP-3601 is an investigational therapeutic peptide designed to target a specific conformation of the parathyroid hormone (PTH) receptor to safely produce sustained and stable levels of calcium in the blood and thereby manage the symptoms of hypoparathyro...
Product Name : AZP-3601
Product Type : Peptide
Upfront Cash : Inapplicable
December 10, 2022
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amolyt Pharma to Present Full Phase 2a Data on AZP-3601 at Upcoming Conferences
Details : AZP-3601 is an investigational therapeutic peptide designed to target a specific conformation of the parathyroid hormone (PTH) receptor to safely produce sustained and stable levels of calcium in the blood and thereby manage the symptoms of hypoparathyro...
Product Name : AZP-3601
Product Type : Peptide
Upfront Cash : Inapplicable
December 10, 2022
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AZP-3601 is an investigational therapeutic peptide designed to target a specific conformation of the parathyroid hormone (PTH) receptor to safely produce sustained and stable levels of calcium in the blood and thereby manage the symptoms of hypoparathyro...
Product Name : AZP-3601
Product Type : Peptide
Upfront Cash : Inapplicable
December 09, 2022
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AZP-3601, a long-acting PTH analog as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly.
Product Name : AZP-3601
Product Type : Peptide
Upfront Cash : Inapplicable
July 09, 2022
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AZP-3601 is an investigational therapeutic peptide designed to target a specific conformation of PTH receptor to safely produce sustained and stable levels of calcium in blood with goal of consequently preventing chronic kidney disease.
Product Name : AZP-3601
Product Type : Peptide
Upfront Cash : Inapplicable
January 09, 2022
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The data demonstrate that AZP-3601 was well-tolerated and daily administration to patients enabled discontinuation of the standard of care while mean serum calcium was maintained within the target range.
Product Name : AZP-3601
Product Type : Peptide
Upfront Cash : Inapplicable
January 06, 2022
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes
Details : The purpose of the study is to confirm and optimize the safety and efficacy of M1Pram in comparison with insulin lispro (Humalog®, Eli Lilly) in regard to glycemic control and body weight reduction.
Product Name : BC LisPram
Product Type : Peptide
Upfront Cash : Inapplicable
October 03, 2021
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imeglimin Hydrochloride
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Metavant Sciences
Deal Size : Undisclosed
Deal Type : Termination
Poxel Regains Imeglimin Rights From Metavant
Details : Metavant will return all rights to Imeglimin to Poxel, as well as all data, materials, and information, including FDA regulatory filings, related to the program. Metavant is not entitled to any payment from Poxel as part of the return of the program.
Product Name : Twymeeg
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 14, 2021
Lead Product(s) : Imeglimin Hydrochloride
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Metavant Sciences
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : Yeast Recombinant Lipase,Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : First Wave BioPharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Creapharm will package, label, and distribute AzurRx’s MS1819 clinical trial drug product for both the upcoming Phase 2b OPTION 2 Monotherapy and the ongoing Phase 2 Combination Therapy Programs.
Product Name : MS1819
Product Type : Enzyme
Upfront Cash : Undisclosed
July 05, 2020
Lead Product(s) : Yeast Recombinant Lipase,Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : First Wave BioPharma
Deal Size : Undisclosed
Deal Type : Agreement